Macias WL - Search Results

1

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM. Macias WL, et al. Crit Care. 2005;9 Suppl 4(Suppl 4):S38-45. doi: 10.1186/cc3747. Epub 2005 Aug 25. Crit Care. 2005. PMID: 16168074 Free PMC article. Review.

2

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Nadel S, et al. Among authors: macias wl. Lancet. 2007 Mar 10;369(9564):836-843. doi: 10.1016/S0140-6736(07)60411-5. Lancet. 2007. PMID: 17350452 Clinical Trial.

3

The development of drotrecogin alfa (activated) for the treatment of severe sepsis.

Macias WL, Yan SB, Grinnell BW. Macias WL, et al. Int J Artif Organs. 2004 May;27(5):360-70. doi: 10.1177/039139880402700504. Int J Artif Organs. 2004. PMID: 15202813 Review. No abstract available.

4

International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W. Sashegyi A, et al. Curr Med Res Opin. 2006 May;22(5):1001-12. doi: 10.1185/030079906X104713. Curr Med Res Opin. 2006. PMID: 16709322

5

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Bernard GR, et al. Among authors: macias wl. Crit Care. 2003 Apr;7(2):155-63. doi: 10.1186/cc2167. Epub 2003 Feb 28. Crit Care. 2003. PMID: 12720562 Free PMC article. Review.

6

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A. Macias WL, et al. Crit Care. 2005;9(6):R607-22. doi: 10.1186/cc3795. Epub 2005 Sep 22. Crit Care. 2005. PMID: 16280057 Free PMC article. Review.

7

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E. Laterre PF, et al. Among authors: macias wl. Crit Care. 2008;12(5):R117. doi: 10.1186/cc7011. Epub 2008 Sep 11. Crit Care. 2008. PMID: 18786266 Free PMC article.

8

Activated protein C and acute kidney injury: Selective targeting of PAR-1.

Gupta A, Williams MD, Macias WL, Molitoris BA, Grinnell BW. Gupta A, et al. Among authors: macias wl. Curr Drug Targets. 2009 Dec;10(12):1212-26. doi: 10.2174/138945009789753291. Curr Drug Targets. 2009. PMID: 19715537 Review.

9

Activated protein C levels in patients with severe sepsis: rebuttal.

Yan SB, Macias WL. Yan SB, et al. Among authors: macias wl. J Thromb Haemost. 2004 Feb;2(2):366. doi: 10.1111/j.1538-7836.2004.0584m.x. J Thromb Haemost. 2004. PMID: 14996020 Free article. No abstract available.

10

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL. Laterre PF, et al. J Crit Care. 2007 Jun;22(2):142-52. doi: 10.1016/j.jcrc.2006.09.007. Epub 2007 Jan 31. J Crit Care. 2007. PMID: 17548026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters